S&P 500   3,957.19 (-0.01%)
DOW   33,819.09 (-0.10%)
QQQ   281.14 (+0.20%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
S&P 500   3,957.19 (-0.01%)
DOW   33,819.09 (-0.10%)
QQQ   281.14 (+0.20%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
S&P 500   3,957.19 (-0.01%)
DOW   33,819.09 (-0.10%)
QQQ   281.14 (+0.20%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
S&P 500   3,957.19 (-0.01%)
DOW   33,819.09 (-0.10%)
QQQ   281.14 (+0.20%)
AAPL   141.52 (+0.25%)
MSFT   241.05 (+0.30%)
META   109.87 (+0.37%)
GOOGL   94.93 (-0.27%)
AMZN   92.61 (+0.21%)
TSLA   182.40 (+0.87%)
NVDA   156.47 (+0.05%)
NIO   11.30 (+7.62%)
BABA   82.66 (+3.51%)
AMD   73.29 (-0.14%)
T   19.04 (+0.16%)
MU   53.69 (-2.59%)
F   13.76 (+0.07%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.46 (+0.40%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   281.07 (+0.04%)
OTCMKTS:UCBJY

UCB - UCBJY Stock Forecast, Price & News

$39.88
-0.21 (-0.52%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$39.78
▼
$40.17
50-Day Range
$33.02
▼
$40.44
52-Week Range
$32.82
▼
$63.94
Volume
9,899 shs
Average Volume
34,897 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.75
UCBJY stock logo

About UCB (OTCMKTS:UCBJY) Stock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Receive UCBJY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJY Stock News Headlines

November 8, 2022 | benzinga.com
UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022
September 24, 2022 | benzinga.com
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
September 22, 2022 | finance.yahoo.com
UCB SA (UCB.BR)
September 17, 2022 | reuters.com
UCB.BR - UCB SA | Stock Price & Latest News | Reuters
September 2, 2022 | benzinga.com
UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress
May 11, 2022 | finance.yahoo.com
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
May 4, 2022 | markets.businessinsider.com
JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)
March 29, 2022 | markets.businessinsider.com
FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
March 28, 2022 | finance.yahoo.com
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
March 28, 2022 | seekingalpha.com
UCB's Fintepla gets FDA approval to treat rare childhood epilepsy
March 7, 2022 | seekingalpha.com
UCB completes $1.9B acquisition of Zogenix
January 21, 2022 | ca.finance.yahoo.com
Zogenix Surges After UCB's $1.9B Acquisition Offer
January 21, 2022 | seekingalpha.com
UCB says second late-stage psoriatic arthritis trial for bimekizumab met main goal
January 20, 2022 | markets.businessinsider.com
Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study
December 18, 2021 | markets.businessinsider.com
Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial
December 18, 2021 | nasdaq.com
UCBJY Real-Time Quotes
October 16, 2021 | finance.yahoo.com
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
August 30, 2021 | finance.yahoo.com
UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older
June 14, 2021 | benzinga.com
Immunology Market to Hit USD 158.69 Billion with 8.1% CAGR by 2028 Backed by Increasing Demand for Biosimilars Globally, reports Fortune Business Insights™
April 23, 2021 | finance.yahoo.com
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
April 23, 2021 | finance.yahoo.com
"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
March 31, 2021 | markets.businessinsider.com
UCB : UCB SA/NV - Convening notice annual shareholders meeting
March 9, 2021 | finance.yahoo.com
Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
See More Headlines
Receive UCBJY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:UCBJY
CUSIP
N/A
CIK
1290640
Web
www.ucb.com
Phone
(322) 559-9999
Fax
N/A
Employees
8,006
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$100.75
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$87.00
Forecasted Upside/Downside
+152.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Jean-Christophe Tellier (Age 63)
    CEO & Exec. Director
    Comp: $4.15M
  • Ms. Sandrine Dufour CFA (Age 56)
    Exec. VP & CFO
  • Ms. Kirsten Lund-Jurgensen (Age 63)
    Exec. VP of Supply & Technology Solutions
  • Dr. Dhavalkumar D. Patel M.D. (Age 61)
    Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. William J. Silbey (Age 63)
    Exec. VP & Gen. Counsel
  • Mr. Jean-Luc Fleurial (Age 57)
    Exec. VP & Chief HR Officer
  • Prof. Iris Low-Friedrich (Age 62)
    Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices
  • Mr. Emmanuel Caeymaex (Age 53)
    Exec. VP of Immunology Solutions & Head of US
  • Mr. Charl van Zyl (Age 55)
    Exec. VP of Neurology Solutions & Head of EU/International
  • Ms. Caroline Vancoillie
    Chief Accounting Officer & CFO of Patient Value Functions

Key Competitors

View All Competitors













UCBJY Stock - Frequently Asked Questions

Should I buy or sell UCB stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" UCBJY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UCBJY, but not buy additional shares or sell existing shares.
View UCBJY analyst ratings or view top-rated stocks.

What is UCB's stock price forecast for 2023?

6 analysts have issued 12 month price targets for UCB's stock. Their UCBJY share price forecasts range from $87.00 to $120.00. On average, they predict the company's stock price to reach $100.75 in the next year. This suggests a possible upside of 152.6% from the stock's current price.
View analysts price targets for UCBJY or view top-rated stocks among Wall Street analysts.

How have UCBJY shares performed in 2022?

UCB's stock was trading at $56.86 at the start of the year. Since then, UCBJY shares have decreased by 29.9% and is now trading at $39.88.
View the best growth stocks for 2022 here.

Are investors shorting UCB?

UCB saw a drop in short interest in November. As of November 15th, there was short interest totaling 2,200 shares, a drop of 40.5% from the October 31st total of 3,700 shares. Based on an average daily trading volume, of 45,700 shares, the days-to-cover ratio is currently 0.0 days.
View UCB's Short Interest.

How often does UCB pay dividends? What is the dividend yield for UCB?

UCB announced a dividend on Saturday, April 23rd. Investors of record on Monday, May 2nd will be paid a dividend of $0.4413 per share on Wednesday, May 18th. This represents a dividend yield of 0.74%. The ex-dividend date of this dividend is Friday, April 29th.
Read our dividend analysis for UCBJY.

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJY."

How do I buy shares of UCB?

Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJY stock can currently be purchased for approximately $39.88.

How many employees does UCB have?

The company employs 8,006 workers across the globe.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche, 60, Anderlecht, Bruxelles Capitale 1070. The official website for the company is www.ucb.com. The company can be reached via phone at (322) 559-9999.

This page (OTCMKTS:UCBJY) was last updated on 11/30/2022 by MarketBeat.com Staff